Jue Pu
Director/Board Member at LEPU BIOPHARMA CO., LTD.
Net worth: 59 M $ as of 2024-05-30
Jue Pu active positions
| Companies | Position | Start | End |
|---|---|---|---|
| LEPU BIOPHARMA CO., LTD. | Director/Board Member | 2020-04-21 | - |
Inspirna, Inc.
 Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | Director/Board Member | 2018-09-30 | - |
Career history of Jue Pu
Former positions of Jue Pu
| Companies | Position | Start | End |
|---|---|---|---|
| CG ONCOLOGY, INC. | Director/Board Member | 2019-02-28 | 2023-09-30 |
| CG ONCOLOGY, INC. | Director/Board Member | 2009-12-31 | 2017-12-31 |
| Founder | 2009-12-31 | 2017-12-31 |
Training of Jue Pu
| The Wharton School of the University of Pennsylvania | Undergraduate Degree |
| Stanford University | Graduate Degree |
Statistics
International
| United States | 5 |
| China | 2 |
Operational
| Director/Board Member | 4 |
| Founder | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| CG ONCOLOGY, INC. | Health Technology |
| LEPU BIOPHARMA CO., LTD. | Health Technology |
| Private companies | 1 |
|---|---|
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Jue Pu
- Experience
